公开(公告)号：US20100187353A1

公开(公告)日：2010-07-29

申请号：US12664549

申请日：2008-06-12

Applicant: Richard Masson ,  Stephane Picard

Inventor： Richard Masson ,  Stephane Picard

IPC: B64C25/62 ,  F16F9/06

CPC classification number: B64C25/60 ,  F16F9/063

Abstract: The invention relates to a shock-absorber for aircraft landing gear, the shock-absorber having two elements (1, 2) mounted to slide telescopically one in the other and defining an internal volume that is filled with hydraulic fluid and with gas, the internal volume being separated into at least two chambers (7, 8) by a separation (5) including at least one throttling orifice (10) through which the hydraulic fluid passes from one chamber to the other while the shock-absorber is being compressed. According to the invention, the separation includes at least one degassing orifice to enable gas to be transferred from one chamber to the other when the landing gear is in the deployed position, the degassing orifice being offset vertically relative to the throttling orifice so as to be located above it when the landing gear is in the deployed position.

Abstract translation: 本发明涉及一种用于飞机起落架的减震器，该减振器具有两个元件（1,2），其安装成可伸缩地彼此滑动并且限定了用液压流体和气体填充的内部容积，内部 体积通过包括至少一个节流孔（10）的分离（5）分离成至少两个腔室（7,8），当减震器被压缩时，液压流体通过该节流口从一个腔室传递到另一个腔室。 根据本发明，分离包括至少一个脱气孔，以使得当起落架处于展开位置时能够将气体从一个室转移到另一个室，脱气孔相对于节流孔垂直偏移，以便于 当起落架处于展开位置时位于其上方。

公开(公告)号：US20090281113A1

公开(公告)日：2009-11-12

申请号：US12442126

申请日：2007-09-20

Applicant: Insa Gathmann ,  Francois-Xavier Mahon ,  Mathieu Molimard ,  Stephane Picard ,  Yanfeng Wang

Inventor： Insa Gathmann ,  Francois-Xavier Mahon ,  Mathieu Molimard ,  Stephane Picard ,  Yanfeng Wang

IPC: A61K31/506 ,  A61P35/02

CPC classification number: A61K31/506 ,  A61K31/00 ,  G01N33/49 ,  G01N2800/52

Abstract: The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed amount of a Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, future patients suffering from a Ph+ leukemia in a manner that a Cmin is achieved in each single patient equal to or higher than the Cmin threshold obtained under step (d).

Abstract translation: 本发明提供了一种在人类患者群体中治疗费城阳性（Ph +）白血病如费城染色体阳性急性淋巴细胞白血病（Ph + ALL）或慢性骨髓性白血病（CML）的方法，包括以下步骤：（a） 将固定量的Bcr-Abl酪氨酸激酶抑制剂（例如伊马替尼）或其药学上可接受的盐给予患有Ph +白血病的人类患者，（b）从所述患者收集至少一种血液样品，（c）测定血浆槽 Bcr-Abl酪氨酸激酶抑制剂或其代谢物的水平（Cmin）以及MMR率，（d）评估MMR的谷浆浓度的鉴别潜力，并鉴定最佳灵敏度和特异性的Cmin阈值，（e ）调节从所述患者群体应用于个体患者的Bcr-Abl酪氨酸激酶抑制剂或其药学上可接受的盐的剂量 以及任选地，患有Ph +白血病的未来患者以等于或高于步骤（d）获得的Cmin阈值的每个单个患者中实现Cmin的方式。

公开(公告)号：US20050097563A1

公开(公告)日：2005-05-05

申请号：US10968542

申请日：2004-10-19

Applicant: Jerome Bidet ,  Anthony Dauguet ,  Stephane Picard

Inventor： Jerome Bidet ,  Anthony Dauguet ,  Stephane Picard

IPC: G06F9/445 ,  G06F1/00 ,  G06F9/44 ,  G06F15/02 ,  G06F17/30 ,  G06F21/60 ,  G06F21/62 ,  G06F21/74

CPC classification number: G06F21/629 ,  G06F21/604 ,  G06F21/62 ,  G06F21/6218 ,  G06F21/74 ,  G06F2221/2105 ,  G06F2221/2141 ,  G06F2221/2149 ,  Y10S707/99932

Abstract: A pocket computer comprising a plurality of programs and data, loading of and access to said programs and data being managed by an operating system. The pocket computer comprises means for selecting one of at least two predefined contexts of use and a context database that comprises a list of associated programs and data for each predefined context of use. In response to selection of a context of use, the operating system interrogates the context database in order to activate from the plurality of programs and data only programs and data associated with said context in the context base.

Abstract translation: 包括多个程序和数据的袖珍计算机，由操作系统管理的所述程序和数据的加载和访问。 袖珍计算机包括用于选择使用的至少两个预定义上下文中的一个的装置和包括用于每个预定使用上下文的相关联程序和数据的列表的上下文数据库。 响应于使用上下文的选择，操作系统询问上下文数据库，以便从多个程序和仅数据的程序和与上下文基础中的所述上下文相关联的数据激活。

公开(公告)号：US20170007605A1

公开(公告)日：2017-01-12

申请号：US15272576

申请日：2016-09-22

Applicant: Insa Gathmann ,  Francois-Xavier Mahon ,  Mathieu Molimard ,  Stephane Picard ,  Yanfeng Wang

Inventor： Insa Gathmann ,  Francois-Xavier Mahon ,  Mathieu Molimard ,  Stephane Picard ,  Yanfeng Wang

IPC: A61K31/506 ,  G01N33/49

CPC classification number: A61K31/506 ,  A61K31/00 ,  G01N33/49 ,  G01N2800/52

Abstract: The present invention provides a method of treating Philadelphia positive (Ph+) leukemia, such as Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia (CML), in a human patient population comprising the steps of (a) administering a predetermined fixed therapeutically effective amount of an Bcr-Abl tyrosine kinase inhibitor, such as Imatinib, or a pharmaceutically acceptable salt thereof to human patients suffering from a Ph+ leukemia, (b) collecting at least one blood sample from said patients, (c) determining the plasma trough level (Cmin) of the Bcr-Abl tyrosine kinase inhibitor or of a metabolite thereof as well as the MMR rates, (d) assessing a discrimination potential of trough plasma concentrations for MMR and identifying a Cmin threshold for optimal sensitivity and specificity and (e) adjusting the dose of the inhibitor of the Bcr-Abl tyrosine kinase or a pharmaceutically acceptable salt thereof applied to the individual patients from said patient population and, optionally, future patients suffering from a Ph+ leukemia in a manner that a Cmin is achieved in each single patient equal to or higher than the Cmin threshold obtained under step (d).

Abstract translation: 本发明提供了一种在人类患者群体中治疗费城阳性（Ph +）白血病如费城染色体阳性急性淋巴细胞白血病（Ph + ALL）或慢性骨髓性白血病（CML）的方法，包括以下步骤：（a） 将固定量的Bcr-Abl酪氨酸激酶抑制剂（例如伊马替尼）或其药学上可接受的盐给予患有Ph +白血病的人类患者，（b）从所述患者收集至少一种血液样品，（c）测定血浆槽 Bcr-Abl酪氨酸激酶抑制剂或其代谢物的水平（Cmin）以及MMR率，（d）评估MMR的谷浆浓度的鉴别潜力，并鉴定最佳灵敏度和特异性的Cmin阈值，（e ）调节从所述患者群体应用于个体患者的Bcr-Abl酪氨酸激酶抑制剂或其药学上可接受的盐的剂量 以及任选地，患有Ph +白血病的未来患者以等于或高于步骤（d）获得的Cmin阈值的每个单个患者中实现Cmin的方式。